DUBLIN--(BUSINESS WIRE)--Dublin - Research and Markets (http://www.researchandmarkets.com/research/03705c61/global_biosimilars) has announced the addition of the "Global Biosimilars Market Forecast to 2015" report to their offering.
The biosimilars industry has been growing stupendously across the globe for past few years. Increasing healthcare costs and rising aging population are driving the industry, which stands at a vivid position and is expected to evolve greatly from its current state. As per the estimations of our latest report, the global biosimilars market will grow at a CAGR of around 52% during 2010-2015. With the governments and private players worldwide stepping in the industry, the market shows bright prospects and immense opportunities to cash in on.
According to Global Biosimilars Market Forecast to 2015, the first-generation biosimilars currently dominate the market, and their second-generation is expected to grow stupendously in the future. Our report provides a thorough study of the biosimilars market, and its segmentation at the product and country level. We have carried out a detailed market-segmentation analysis in the study, which presents forecasts on the first-generation biosimilars. Key developments in each segment have also been highlighted in it to tell what is going on' in the market.
For key regulated and unregulated markets including the US, Europe, India, China and Korea, the geographic-segmentation has been included. Our research has studied the overall industry performance and key biosimilar products in the market, and found that patent expirations offer a huge potential to new market entrants. The recent industry activities have been tracked, and the regulatory scenario has been analyzed to provide an impartial picture of the industry to clients.
Companies Mentioned
- Hospira
- Stada Arzneimittel
- Hexal AG
- Ratiopharm GmbH
- Sandoz GmbH
- Bioton
- Dr.Reddy's Labs (DRL)
- Intas Pharmaceuticals Ltd.
- Biocon Limited
- Wockhardt Limited
- Shantha Biotechnics Limited
- Reliance Life Sciences
- 3 SBio Inc.
- Beijing Tri-Prime
- Beijing SL Pharmaceutical Co., Ltd.
- Shandong Kexing Biological Products Co., Ltd
- Hangzhou Jiuyuan Gene Engineering
- LG Life Sciences
- Celltrion Pharm Inc.
- Dong-A Pharmaceutical Co., Ltd
- Teva
- Cangene Corporation
- Microbix Biosystems, Inc.
For more information visit http://www.researchandmarkets.com/research/03705c61/global_biosimilars